Drugs / HRS-7535
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07269756 | Dec 2025 → Mar 2026 | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06961643 | Jun 2025 → Jan 2026 | diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06819488 | Feb → Apr 2025 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06727838 | Dec 2024 → Jan 2025 | diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06495931 | Jul → Aug 2024 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06422039 | May → Aug 2024 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06132204 | Dec 2023 → Mar 2024 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05347758 | May → Sep 2022 | — | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06621316 | Oct 2024 → May 2025 overdue | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06820099 | Apr 2025 → Dec 2026 expected | mild heart failure | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06671821 | Nov 2024 → Aug 2025 | — | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06415214 | Jun 2024 → Jul 2025 | diabetic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06393348 | May → Nov 2024 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06250946 | Feb 2024 → Jan 2025 | morbid obesity | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05759897 | Feb → Dec 2023 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07625774 | Jul 2026 → May 2031 expected | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07528027 | May 2026 → Dec 2027 expected | — | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06904105 | Apr 2025 → May 2026 overdue | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06589765 | Sep 2024 → May 2026 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06672172 | Sep 2024 → Nov 2025 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7535 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672172 ↗ |
| Action | Activate | “To evaluate the efficacy and safety of HRS-7535, an oral nonpeptide GLP-1 RA, as add-on therapy among adults with type 2 diabetes inadequately controlled with metformin.” PMID 42234428 ↗ Jun 2026 |
| Modality | Small molecule | “HRS-7535 is an orally active small-molecule glucagon-like peptide-1 receptor agonist” PMID 42331800 ↗ Jun 2026 |
| Route | Oral | “Participants were randomized (1:1:1:1:1) to once-daily oral HRS-7535 (15, 30, 60, or 90 mg) or matching placebo.” PMID 42234428 ↗ Jun 2026 |